Active Surveillance: Is it an Appropriate Approach for Thyroid Cancer?
In patients with thyroid cancer, active surveillance has been controversial because surgery is the standard of care.
Endocrine Cancer
ENDOCRINE CANCER ADVISOR
FEATURED CONTENT
-
-
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott. -
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%… -
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services. -
Opinion: Understanding the FDA’s Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
ENDOCRINE CANCER NEWS
Vitiligo May Be Associated With Reduced Risk of Internal Cancer
Molecular Testing May Prevent Unnecessary Treatment of Suspicious for Malignancy Thyroid Nodules
Lobectomy Rates for Low-Risk DTC Are Rising
Childhood Radiation-Induced Thyroid Cancer Does Not Lower All-Cause Survival
RET Inhibitor May Be Effective in RET-Altered Thyroid Cancers
MORE ENDOCRINE CANCER INFORMATION
Heart Failure During Breast Cancer Management: A Case Study
CAPRELSA (vandetanib) for Medullary Thyroid Cancer
SUTENT (sunitinib) for GIST, Advanced RCC and Advanced pNET
The Treatment Landscape of Breast Cancer
IBRANCE (palbociclib) for Metastatic Breast Cancer
TYKERB (lapatinib) for Metastatic Breast Cancer
IXEMPRA® (ixabepilone) for Metastatic or Locally Advanced Breast Cancer
HALAVEN (eribulin mesylate) for Refractory Metastatic Breast Cancer
Want to read more?
Please login or register first to view this content.
Next post in Endocrine Cancer
